Spineguard (XPAR:ALSGD) Revenue: €3.76 Mil (TTM As of Dec. 2025)


What is Spineguard Revenue?

Spineguard XPAR:ALSGD +1.83% Revenue is €3.76 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Spineguard's revenue for the six months ended in Dec. 2025 was €1.64 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €3.76 Mil. Spineguard's Revenue per Share for the six months ended in Dec. 2025 was €0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.05.

Warning Sign:

Spineguard revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Spineguard was -41.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -29.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -21.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was -29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Spineguard's highest 3-Year average Revenue per Share Growth Rate was 14.40% per year. The lowest was -48.80% per year. And the median was -16.70% per year.


Spineguard  (XPAR:ALSGD) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Spineguard Revenue Related Terms


Spineguard Revenue Historical Data

* Premium members only.

The historical data trend for Spineguard's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spineguard Revenue Chart

Spineguard Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.41 5.60 4.31 4.65 3.76

Spineguard Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 2.45 2.20 2.12 1.64

XPAR:ALSGD vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Spineguard's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spineguard Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spineguard's Revenue distribution charts can be found below:

* The bar in red indicates where Spineguard's Revenue falls into.



Spineguard Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €3.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of €3.76 Mil mean?
Spineguard (XPAR:ALSGD) has a Revenue of €3.76 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Spineguard and its competitors.
Is Spineguard's Revenue too high?
Spineguard's current Revenue is €3.76 Mil.
How does Spineguard's Revenue compare to ABT and SYK?
Spineguard's Revenue of €3.76 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Spineguard and its competitors. Spineguard's current Revenue is €3.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spineguard stock overvalued right now?
Based on GuruFocus' analysis, Spineguard (XPAR:ALSGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.08 — trading 16.5% below its estimated fair value. The current Revenue is €3.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Spineguard (XPAR:ALSGD), the current Revenue is €3.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spineguard Business Description

Other Exchanges 6W5:Germany
Address 10 Cours Louis Lumiere, Vincennes, FRA, 94300
Spineguard is engaged in the design and production of medical instruments used for spinal surgeries. It is deploying its proprietary radiation-free real time sensing technology DSG (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. It designs, develops and markets medical devices embedding its technology. The group is developing DSG digital technology for real-time surgical guidance without X-rays to improve the safety and simplify the placement of bone implants, pedicle screws, and smart drills. SpineGuard is extending the applications of its DSG technology to anterior scoliosis treatment, sacroiliac joint fusion, and dental implantology.